← Back to Search

Virus Therapy

Vaccine for COVID-19 (COVID-19 Trial)

Verified Trial
Phase 2 & 3
Recruiting
Research Sponsored by Novavax
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have you been sick in the last 12 months (e.g., fever, chills, sore throat, dry cough, etc..)?
Be between 18 and 65 years old
Must not have
Have you received an FDA-authorized vaccine for COVID-19?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28 to day 180
Awards & highlights

Summary

This trial tests a new COVID-19 booster vaccine for adults who either had previous mRNA vaccines or had COVID-19 but were not vaccinated. The vaccine aims to improve protection against the Omicron XBB.1.5 variant by enhancing the immune response.

Who is the study for?
This trial is for adults over 18 who've had an mRNA COVID-19 vaccine or are seropositive but unvaccinated. Participants must not join other SARS-CoV-2 studies during this time and should have no autoimmune conditions, allergies to vaccine ingredients, or history of myocarditis/pericarditis.
What is being tested?
The study tests a booster dose of the XBB.1.5 COVID-19 vaccine in previously vaccinated individuals and a single dose in those unvaccinated but with natural immunity. It's open-label, meaning everyone knows which treatment they're getting.
What are the potential side effects?
Potential side effects may include typical reactions like soreness at the injection site, fever, fatigue, headaches, muscle pain, chills and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been sick with symptoms like fever or cough in the last year.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28 to day 180
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 to day 180 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part 1: Pseudovirus neutralization (inhibitory dilution at a concentration of 50%; ID 50 ) to the NVX-CoV2601 vaccine
Part 1: Seroresponse Rates (SRRs) in ID 50 titers to the NVXCoV2601 vaccine
Part 2: ID 50 (Geometric Mean Titers) GMTs to the XBB.1.5 Omicron subvariant
+1 more
Secondary study objectives
Part 1: Anti-S immunoglobulin G (IgG) geometric mean concentrations (GMCs, EU/mL) to the NVX-CoV2601 vaccine at relevant time points
Part 1: ID 50 GMTs to the XBB.1.5 Omicron subvariant
Part 1: ID 50 geometric mean fold rise (GMFR) to the XBB.1.5 Omicron subvariant at relevant time points (Days 28 and 180) from baseline (Day 0).
+9 more

Side effects data

From 2023 Phase 4 trial • 267 Patients • NCT05007041
8%
COVID-19 Infection
7%
Upper Respiratory Infection
1%
Cardiovascular Accident (CVA), Unspecified Mechanism
1%
Left partial cranial nerve III palsy
1%
Acute Hyperkalemia
1%
Shortness of Breath
1%
Acute pulmonary embolism and acute deep vein thrombosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Recombinant Zoster Vaccine (RZV) and High-Dose Quadrivalent Influenza Vaccine
Recombinant Zoster Vaccine (RZV) and Quadrivalent Adjuvanted Influenza Vaccine

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group-A XBB.1.5 Vaccine (Booster)Experimental Treatment1 Intervention
The Monovalent [5 μg/50 μg] NVX-CoV2601 XBB.1.5 Vaccine (Booster)
Group II: Group-B The monovalent XBB.1.5 Vaccine (Single Dose).Active Control1 Intervention
Group-B The monovalent [5 μg/50 μg] NVX-CoV2601 XBB.1.5 Vaccine (Single Dose).

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for COVID-19, such as the XBB.1.5 SARS-CoV-2 recombinant spike protein nanoparticle vaccine adjuvanted with Matrix-M™, work by enhancing the immune system's ability to recognize and combat the virus. This vaccine presents the spike protein to the immune system and uses the Matrix-M™ adjuvant to boost the immune response. Similar mechanisms are seen in mRNA vaccines, which instruct cells to produce the spike protein, and antiviral drugs like Remdesivir, which inhibit viral replication. Monoclonal antibodies provide direct immunity by targeting the virus. These treatments are essential as they help prevent infection, reduce viral load, and alleviate severe symptoms, ultimately improving patient outcomes.
The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.

Find a Location

Who is running the clinical trial?

NovavaxLead Sponsor
49 Previous Clinical Trials
108,044 Total Patients Enrolled
Clinical DevelopmentStudy DirectorNovavax, Inc.
36 Previous Clinical Trials
86,999 Total Patients Enrolled

Media Library

XBB.1.5 Vaccine (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05975060 — Phase 2 & 3
Coronavirus Research Study Groups: Group-A XBB.1.5 Vaccine (Booster), Group-B The monovalent XBB.1.5 Vaccine (Single Dose).
Coronavirus Clinical Trial 2023: XBB.1.5 Vaccine Highlights & Side Effects. Trial Name: NCT05975060 — Phase 2 & 3
XBB.1.5 Vaccine (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05975060 — Phase 2 & 3
~317 spots leftby Oct 2025